AllDocs -> cancers

GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator) ; as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD Page 2 CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT OF UNRESECTABLE NON-SMALL CELL LUNG CANCER PURPOSE: • To minimize the inappropriate practice variations. • To justify the financial costs of therapy in relation to its outcome • To clarify the optimal management of patients with unresectable disease • To defme what is important to patients, the quality or the quantity of survival in situations where palliation, not cure, is the goal. Introduction: Lung cancer remains worldwide a public health problem for both men and women.The impact on and cost of this disease to society are staggering.In the USA alone, an estimated 171,600 new cases were diagnosed ...

Awarenes 1 L ung Cancer Awareness Month (LCAM) is a national campaign dedicated to increasing attention to lung cancer issues and ending the stigma of lung cancer . The best way to accomplish that is by spreading the word about lung cancer . And the best way to do that is through the work of local volunteer advocates and grass- roots activity with the Lung Cancer Alliance (LCA) as the central point of organization and information – the destination for everything needed to make LCAM a success. As you read this, Lung Cancer Awareness Month is already underway. It is hard to believe that the LCA has been in Washington, D.C. for almost a year now. We’ve established our new headquarters and we’re ready to take the next step – moving to a high level of public aware- ness and grassroots advocacy. Volunteer advocates are ...

lung cancer LUNG CANCER RADIOLOGICAL FEATURES TYPES OF LUNG CANCER Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Small cell carcinoma RADIOGRAPHIC PRESENTATIONS OF LUNG CANCER Mass or nodule Atelectasis ( lung collapse) Non-resolving pneumonia Mediastinal lymph node enlargement THE SOLITARY PULMONARY NODULE LUNG NODULE DIFFERENTIAL DIAGNOSIS Lung cancer Metastatic cancer Granuloma Hamartoma LUNG NODULE MALIGNANT FEATURES New or growing ...

Lung cancer is not an AIDS-defining illness, but evidence from the UK and other countries shows that lung cancer is more common in HIV-positive people than the general HIV-negative population. Before effective anti-HIV treatment (often known as highly active antiretroviral therapy, or HAART for short) became available, it was already clear that lung cancer occurred more frequently in HIV-positive patients.With the introduction of HAART, lung cancer has become more common. However, it is important to emphasise that this is because people with HIV are living longer, healthier lives and not dying early because of HIV-related causes.There is no evidence that HAART causes lung cancer or any other cancer . It is also important to remember that lung cancer is very rare in HIV-positive people. At the UK’s largest HIV clinic only eleven people have ever been diagnosed with lung cancer ...

LUNG CANCER AN INTERNATIONAL JOURNAL FOR LUNG CANCER AND OTHER THORACIC MALIGNANCIES Lung Cancer aims to provide with the most recent information on lung cancer and other thoracic malignancies. The journal publishes full-length articles of original research on clinical and basic science aspects of topics represented by the fields of interest of lung cancer . Key topics include: • Prevention • Chemotherapy • Epidemiology and Etiology • Radiotherapy • Basic Biology • Combined Treatment Modalities • Pathology • Other Treatment Modalities • Clinical assessment • Reviews • Surgery • Miscellaneous AIMS & SCOPE TARGET AUDIENCE Clinical Oncologists, Internists, Radiologists, ...

Lung Cancer Screening Exam Special Instructions: Your appointment is scheduled for: Day: _ Time: If you cannot keep this appointment, please call (563) 359-3931 to cancel or reschedule. Driving Directions 1970 E. 53rd St., Davenport If you are approaching from the East: Turn right on Spring Street (just west of TPC’s building). Our parking lot entrance will then be on your left. If you are approaching from the West: Turn left (north) on Eastern Avenue at the stop- light. Proceed two blocks to 54th St. and turn right. Follow 54th St. as it runs into Spring St. Our parking lot entrance will be on your right before you reach the stop sign at 53rd St. © 2003 Radiology Group PC, SC Imaging Center. E. 54th Street 53rd Street Jersey Ridge Road Easter n A venue Spring Str ...

Identification of candidate DNA methylation biomarkers in lung cancer using universal bead arrays. Marina Bibikova 1 ,Zhenwu Lin 2 , Lixin Zhou 1 ,Eugene Chudin 1 , Eliza Wickham Garcia 1 , Bonnie Wu 1 , Neal J. Thomas 2 , Yunhua Wang 2 ,Ekkehard Vollmer 3 , Torsten Goldmann 3 , Carola Seifart 4 , David L. Barker 1 , Mark S. Chee 1 , Joanna Floros 2 and Jian-Bing Fan 1 . 1 Illumina, Inc., San Diego, CA 92121, USA; 2 Pennsylvania State University College of Medicine, Hershey, PA 17033, USA; 3 Clinical and Experimental Pathology, Research Center Borstel, 23845 Borstel, Germany; 4 Department of Internal ...

DNA methylation profiling in lung cancer using universal bead arrays Marina Bibikova 1 ,Zhenwu Lin 2 , Lixin Zhou 1 ,Eugene Chudin 1 , Eliza Wickham 1 , Dennis Doucet 1 , Neal Thomas 2 , Yunhua Wang 2 ,Ekkehard Vollmer 3 , Torsten Goldmann 3 , Carola Seifart 4 , David L. Barker 1 , Mark S. Chee 1 , Joanna Floros 2 and Jian-Bing Fan 1 1 Illumina, Inc., 9885 Towne Centre Drive, San Diego, CA 92121; 2 ThePennsylvania State University College of Medicine, 500 University Drive, Hershey, PA 17033; 3 Clinical and Experimental Pathology, Research Center Borstel, Parkallee, 23845 Borstel, Germany; 4 Department of Internal ...

High-throughput DNA methylation profiling using universal bead arrays M. Bibikova 1 ,Z. Lin 2 , L. Zhou 1 ,E. Chudin 1 , E. Wickham 1 , B. Wu 1 , D. Doucet 1 , N. Thomas 2 , Y. Wang 2 ,E. Vollmer 3 , T. Goldmann 3 , C. Seifart 4 , D. L. Barker 1 , M. S. Chee 1 , J. Floros 2 and J.-B. Fan 1 . 1 Illumina, Inc., San Diego, CA; 2 Penn State University, Hershey, PA; 3 Clinical Research Center, Borstel, Germany; 4 Philipps-University of Marburg, Germany. DNA methylation is widespread and plays a critical role in the regulation of gene expression in development, differentiation and diseases. ...

Risk of Lung Cancer and Leukemia from Exposure to Ionizing Radiation and Potential Confounders Among Workers at the Portsmouth Naval Shipyard Yiin JH, Schubauer-Berigan MK, Silver SR, Daniels RD, Kinnes GM, Zaebst DD, Couch JR, Kubale TL, Chen P-H ABSTRACT Significantly elevated lung cancer deaths and statistically significantly positive linear trends between leukemia mortality and radiation exposure were reported in a previous analysis of Portsmouth Naval Shipyard workers. The purpose of this study was to conduct a modeling-based analysis that incorporates previously unanalyzed confounders in exploring the exposure-response relationship between cumulative external ionizing radiation exposure and mortality from these cancers among radiation-monitored workers in this cohort. The main analyses were carried out with Poisson regression fitted with maximum likelihood in linear excess relative ...

63 Lung Cancer 11 11.1. INTRODUCTION AND SUMMARY Lung cancer incidence and mortality were almost the same, with an overall mortality/incidence ratio of 91.3% or a survival of only 8.7% (Table 11.1). For the first time since registration of lung cancers began, the number of cases exceeded that of deaths. This may reflect more accurate certification of deaths or the continuing decline in lung cancer mortality. Incidence in males shows a definite downward trend of almost 5% per year. Female rates have increased by 0.4% per year since 1994, but this trend is not statistically significant. Table 11.1. Summary of incidence and mortality statistics: lung cancer INCIDENT CASES DEATHS males females both sexes males females both sexes All cancers (invasive, in situ and uncertain) (ICD-O-2 C34) 1997 cases 909 ...

Conveniently Located The University of Kansas Hospital is located one mile south of Interstate 35 at 39th and Rainbow Boulevard in Kansas City, Kan., and is easily accessible from both sides of the state line. The U n i v ersit y of K ansas H ospital www.kumed.com 3901 Rainbow Blvd. Kansas City, KS 66160 For More Information To make an appointment with one of The University of Kansas Hospital’s lung cancer experts, call (913) 588-1227 or toll free (800) 332-6048. For more information about the hospital’s services, visit our Web site at www.kumed.com. • A team of experts for each patient • The newest treatment options • Access to clinical trials • Nationally recognized cancer care Lung Cancer Care for the Whole Person Care for the Whole ...

Lung Cancer – Public Awareness Raising Jesme Baird , MB ChB, MBA The Roy Castle Lung Cancer Foundation Page 2 Lung Cancer – A Common Disease of Modern Times “ Is it worthwhile to write a monograph on the subject of primary malignant tumours of the lung ? On one point, however, there is nearly complete consensus of opinion, and that is that primary malignant neoplasms of the lungs are among the rarest forms of the disease . This latter opinion of the extreme rarity of primary tumours has persisted for centuries.” . [Adler, Primary Malignant Growths of the Lungs and Bronchi: A Pathological and Clinical Study. Longmans, Green & Co., London, 1912 ] Page 3 UK Cancer Incidence (2001) [CRUK Information Resource ...

OmniGuide Announces First Customer of Revolutionary Technology that Shrinks Lung Cancer Tumors Boston’s Brigham and Women’s Hospital Purchases OmniGuide Fibers for Lung Cancer Treatments Cambridge, MA – March 10, 2006 – OmniGuide, Inc. ( www.Omni-Guide.com ) announced today the first purchase of OmniGuide Fibers by Brigham and Women’s Hospital (BWH). OmniGuide is now an official supplier of Partners HealthCare, Inc. The OmniGuide Fiber, a revolutionary optical fiber for flexibly guiding CO 2 laser light that was developed at MIT 1 , was recently used for completing the first-ever bronchial surgery for treatment of malignant airway obstruction using a CO 2 laser delivered through a flexible bronchoscope. Raphael Bueno, MD, associate chief of Thoracic Surgery at BWH and associate professor of Surgery at Harvard Medical School, performed the procedure. ...

Indian Journal of Clinical Biochemistry, 2006, 21 (1) 173-176 Indian Journal of Clinical Biochemistry, 2006 173 SIGNIFICANCE OF TUMOR MARKERS IN LUNG CANCER P.P. Mumbarkar, A.S. Raste, M.S. Ghadge Department of Biochemistry, Tata Memorial Hospital, Parel, Mumbai ABSTRACT The objective was to test the utility of the cytokeratins CYFRA 21-1, tissue polypeptide specific antigen (TPS), Neuron specific enolase (NSE) and Carcino Embryonic antigen (CEA) in patients with lung cancer and in the pleural fluid of the patients with lung cancer and also the predicting ability of these tumor markers with respect to the histological types [including non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] and pathological stages. 40 normal subjects and 222 cases of histological proven lung cancer were studied. The findings suggest that TPS and CYFRA 21-1, are useful ...

Interventions Other than Smoking Cessation to Prevent Lung Cancer C HAPTER 64 By Brenda J. Morrison Page 2 Interventions Other than Smoking 64 Cessation to Prevent Lung Cancer Prepared by Brenda J. Morrison, PhD 1 T he primary prevention of lung cancer through smoking cessation must be the long-term goal of preventive health care. However, many people who have overcome their addiction to tobacco or who have reduced their tobacco use are still at risk for lung cancer because of the number of years that they did smoke. Therefore, this chapter examines primary and secondary preventive interventions other than the modification of smoking behaviour. Lower rates of lung cancer are associated with some components ...

***MEDIA ADVISORY*** On behalf of lung cancer patients, survivors, their caregivers, and those at risk for the disease, the Lung Cancer Alliance (LCA) extends our most sincere condolences to the Reeve family for their loss. A devoted supporter of her husband during his battle with spinal cord injury, Dana Reeve’s courageous decision to publicly announce her own lung cancer diagnosis seven months ago has helped raise awareness for others with the disease. “Dana Reeve was a woman of true grace under pressure as she underwent treatment for lung cancer ,” said Laurie Fenton, president of the Lung Cancer Alliance. “Sadly, it takes her death, coming just seven months after diagnosis, and the fact that she had never smoked, to let the public see the real picture of lung cancer which they are not getting from the public health establishment. Lung cancer continues to be portrayed as a self-induced cancer ...

BCCA Protocol Summary for Treatment of Limited Stage Small Cell Lung Cancer (SCLC) with Etoposide and Cisplatin (EP) and Early Thoracic Irradiation (Interim Version) Protocol Code: LUPESL Tumour Group: Lung Contact Physician: Dr. Nevin Murray ELIGIBILITY : Limited stage SCLC STAGING : CXR and/or CT thorax Abdominal U/S or CT Bone scan CT brain Bone marrow aspirate for significant cytopenia and/or myelophthisic blood smear TESTS : Baseline: CBC & differential, platelets, creatinine, liver function tests, bilirubin Before each treatment: CBC & differential, platelets, creatinine If clinically indicated: bilirubin PREMEDICATIONS : Antiemetic protocol for High Moderate emetogenic chemotherapy protocols as long as cisplatin dose is not = 50 mg. If cisplatin is = 50 mg use antiemetic protocol for Highly ...

California Department of Health Services Healthy California 2010 Focus Area 3: Lung Cancer Objective 3-2 targets an overall reduction in the lung cancer death rate to 44.9 per 100,000 population. California’s age-adjusted death rates for lung cancer declined significantly from 46.7 per 100,000 population in 2000 to 40.6 per 100,000 in 2004 (Figure 3-2, Table 3-2). California's lung cancer death rates have declined to a level below the HP2010 target of 44.9 per 100,000 population as of 2002, and this objective is being achieved for the total population. Age-adjusted lung cancer death rates for males are significantly higher than rates for females, and also significantly higher than the HP2010 target. The death rates for both genders declined significantly between 2000 and 2004: the rate for males declined from 59.1 per 100,000 population in 2000 to 49.4 per 100,000 in 2004; ...

Case Report Second Primary Lung Cancer with Tuberculosis Rameshchandra Sahoo, Vishak Acharya K., Dinesh Pai Kasturi 1 , Flora D. Lobo 2 and Hema Kini 2 Departments of TB and Respiratory Diseases, Radiotherapy 1 and Pathology 2 , Kasturba Medical College and Hospital, Mangalore, India ABSTRACT We report a rare case of second primary lung cancer presenting metachronoulsy in a patient with laryngeal cancer . Though regional recurrence and second primary neoplasm of the upper aerodigestive tract are common following laryngeal cancers, second primary cancers of the lung are uncommon. Adding to the rarity of the case was the presence of concurrent active pulmonary tuberculosis with second primary neoplasm of the lung . [Indian J Chest Dis Allied Sci 2006; 48: 63-66] Key words: Lung cancer ...

PUBLIC HEALTH FACT SHEET Lung Cancer What is Lung Cancer ? Lung cancer typically begins as a tiny spot on the inner lining of a bronchial tube. It can take many years for lung cancer to develop and be discovered. Lung cancer is the leading cause of cancer deaths for both men and women. What are the Symptoms of Lung Cancer ? • Constant chest pain • Persistent cough • Blood in saliva • Wheezing • Shortness of breath during routine activities • Hoarseness • Fever • Neck enlargement • Weight loss • Arm and shoulder pain • Repeated pneumonia and bronchitis What are the Risk Factors for Lung Cancer ? • Smoking • Second hand smoke • Air pollution • Occupational exposure to hazardous agents, such as asbestos • Scarred area from a previous inflammation • Exposure to asbestos • Exposure to radon ...

Illinois Department of Public Health q 535 West Jefferson Street q Springfield, Illinois 62761 q 217.782.3300 www.idph.state.il.us q TTY800.547.0466 LUNG CANCER FA C T S E v e ry Breath Counts 3 FACTS Lung cancer is the leading cause of cancer death. In Illinois, between 1973 and 1992, the death rate from lung cancer rose more than the rate for all other cancers combined, including breast, prostate and colorectal cancers. In Illinois, pro- jections for 2001 indicate that there will be more than 8,540 new cases of invasive lung cancer and more than 7,000 people will die. Experts predict that in the next four years, twice as many women will die from lung cancer as from breast cancer . The lungs are large and cancer can grow in them for a long time, often for as long ...

Introduction Lung cancer was the third most common cancer amongst Australian men, and the fourth most common cancer amongst Australian women in 2000. It was the most common cause of death amongst men and the second most common cause of death amongst women in that year. 1 These figures reflect an alarming rise in the number of women diagnosed and dying from lung cancer ; the increase in these rates is due to increased smoking rates among women. Function and structure of the lungs The lungs are two sponge-like organs within the chest cavity. The lungs are responsible for bringing air in and out of the body. They absorb oxygen from the air that is breathed in and expel carbon dioxide in the air that is breathed out. With each inhalation air passes through the trachea (or windpipe) into the two bronchi (or main air passages) supplying each lung . These bronchi ...

Show your support and sign up to the Charter’s demands Lung Cancer Patients' Charter The Lung Cancer Patients' Charter It is the fundamental right of every patient to be treated with dignity and respect. All patients have the right to: 1. Have the profound impact of lung cancer acknowledged by healthcare professionals, policy makers, politicians and the public. This will be achieved by: o A nationwide lung cancer public awareness programme to make sure patients understand the urgency of early presentation and diagnosis o Educating GPs and other healthcare professionals on the signs and symptoms of lung cancer o Raising the awareness of healthcare professionals and social services, of the emotional and practical difficulties experienced by lung cancer patients and their carers o Securing serious funding for ...

Lung Cancer in Georgia, 1999-2002 Page 2 Acknowledgments Georgia Department of Human Resources ... B. J. Walker, Commissioner Division of Public Health.. Stuart Brown, M.D., Director Epidemiology Branch....... Susan Lance, D.V.M, M.P.H., Director Chronic Disease, Injury, and Environmental Epidemiology Section. John Horan, M.D., M.P.H., Chief Georgia Comprehensive Cancer Registry. A. Rana Bayakly, M.P.H., Program Director Chrissy McNamara, M.S.P.H., Epidemiologist Simple Singh, M.D., M.P.H., Epidemiologist Chronic Disease Prevention and Health Promotion Branch Kimberly Redding, MD, MPH, Acting Director Kenneth Ray, M.P.H., Project Manager Argie Figueroa, M.Sc., Epidemiologist We would like to thank all of the hospitals in Georgia that contributed data to the Georgia Comprehensive Cancer Registry. Without their hard work, this report ...

1 The second Kyoto Lung Cancer Forum Preface It is great honor and pleasure for all of us, participants, to have the second conference of "Kyoto Lung Cancer Forum" also this year. The treatment of lung cancer is now coming to so-called “individualization”. The title of the Second Kyoto Lung Cancer Forum is “MOLECULAR TARGETING FOR LUNG CANCER ”. In the conference we are intending to have presentations concerning Dr. Swisher from MD Anderson cancer research center will lecture on gene therapy strategies for lung cancer , especially p53 gene therapy. Dr. Saya from Kumamoto university and Dr. Takenaka of Kyoto university will speak about the candidates of new target genes, CD44 and RECK. Interestingly both of them are involved to regulation of extra-cellular matrix and play a critical role in cancer invasion. Then, Dr. Sekido from Nagoya University will speak ...

Press Contact Kay Cofrancesco 202-463-2080 kcofrancesco@lungcanceralliance.org LUNG CANCER ALLIANCE ISSUES INAUGURAL REPORT CARD ON LUNG CANCER Nation’s Number One Cancer Killer Receives Failing Marks on Key Benchmarks Washington, DC, Jan. 19, 2006: The Lung Cancer Alliance (LCA), the only national non- profit organization dedicated solely to advocating for people living with lung cancer or those at risk for the disease, today issued the first Report Card on Lung Cancer , an assessment of progress being made in the battle against this lethal disease. The majority of grades received were failing. Lung cancer is the number one cancer killer, resulting in 30 percent of all cancer deaths and killing more people annually than breast, prostate, colon, liver, and kidney cancers – combined. “ Lung cancer is the most lethal of all major cancers,” ...

260 Am J Epidemiol 2005;161:260–270 American Journal of Epidemiology Copyright © 2005 by the Johns Hopkins Bloomberg School of Public Health All rights reserved Vol. 161, No. 3 Printed in U.S.A. DOI: 10.1093/aje/kwi034 Predictors of Lung Cancer among Asbestos-exposed Men in the ß-Carotene and Retinol Efficacy Trial Mark R. Cullen 1 , Matt J. Barnett 2 , John R. Balmes 3 , Brenda Cartmel 1 , Carrie A. Redlich 1 , Carl A. Brodkin 4 , Scott Barnhart 4 , Linda Rosenstock 5 , Gary E. Goodman 2 ,6 , Sam P. Hammar 7 , Mark D. Thornquist 2 , and Gilbert S. Omenn 8 ,9 1 Occupational ...

Centre for Clinical Research in Cancer Victorian Cooperative Oncology Group Key Published Articles Listing — Lung Cancer (2000–2003) Title & Abstract Author Journal A model for decision making for the use of radiotherapy in lung cancer Abstract: To develop an evidence-based benchmark for the use of radiotherapy in lung cancer , we did a systematic review of treatment guidelines on radiotherapy for lung cancer . We then constructed an optimum use of radiotherapy "tree" from epidemiological data, which shows the proportion of patients with clinical attributes indicating that they would benefit from radiotherapy. We calculated that the proportion of patients with lung cancer in whom radiotherapy is indicated (according to the best available evidence) is 76%. We then compared this ideal rate with the actual rates of use of radiotherapy for lung cancer in Australia, ...